Jade Biosciences | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.14 12:15
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.48.

EBIT: As of FY2025 Q3, the actual value is USD -29.66 M.

Segment Revenue

  • Jade Biosciences, Inc. has not generated any revenue from product sales as of September 30, 2025.

Operational Metrics

  • Net Loss: The company reported a net loss of $25.2 million for the three months ended September 30, 2025, and $95.5 million for the nine months ended September 30, 2025.
  • Operating Expenses: Total operating expenses were $27.4 million for the three months ended September 30, 2025, and $78.6 million for the nine months ended September 30, 2025.
  • Research and Development Expenses: R&D expenses were $22.0 million for the three months ended September 30, 2025, and $64.6 million for the nine months ended September 30, 2025.
  • General and Administrative Expenses: G&A expenses were $5.4 million for the three months ended September 30, 2025, and $14.0 million for the nine months ended September 30, 2025.

Cash Flow

  • Net Cash Used in Operating Activities: - $61.0 million for the nine months ended September 30, 2025.
  • Net Cash Used in Investing Activities: - $148.8 million for the nine months ended September 30, 2025.
  • Net Cash Provided by Financing Activities: $190.6 million for the nine months ended September 30, 2025.

Unique Metrics

  • Investments: As of September 30, 2025, the company had investments totaling $148.8 million.

Future Outlook and Strategy

  • Core Business Focus: Jade Biosciences, Inc. plans to advance its existing and future product candidates through preclinical and clinical development, including potential expansion into additional indications.
  • Non-Core Business: The company is exploring additional opportunities to enhance its capabilities and expand its development pipeline or add development or commercialization capabilities.
  • Priority: The company expects that its existing cash and cash equivalents, and investments, combined with gross proceeds from recent financing, will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least 12 months from the date these unaudited condensed consolidated financial statements were issued.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.